Official and authoritative background links used for intake education.
Elmiron lawsuit documentation and vision damage intake checklist
Elmiron reviews focus on prescription history, duration of use, and eye damage or vision loss diagnosis records that may be associated with long-term pentosan polysulfate use.
Elmiron lawsuits are civil cases filed by people who took Elmiron and later suffered maculopathy or other major eyesight disorders. Janssen Pharmaceuticals allegedly knew about the potential of eye injury but failed to sufficiently notify the public, according to Elmiron lawsuits.

Maculopathy, retinopathy and other vision problems
Janssen Pharmaceuticals, subsidiary of Johnson & Johnson
Beginning stages of litigation
- Blurred vision
- Degenerative maculopathy
- Halo vision
- Macular retinopathy
- Macular/pattern dystrophy
- Maculopathy
- Metamorphopsia
- Pigmentary maculopathy
- Reduced night vision
- Retinal pigment epithelium atrophy
- Retinopathy
- Scotoma
- Unilateral or bilateral blindness
- Vision impairment
- Vision loss
Lawyers are considering lawsuits from persons who used Elmiron for at least two years and developed visual difficulties, particularly if they took it from 2018 to the present.
These vision impairments have to have started while you were using Elmiron or within a year of stopping it. If you stopped using Elmiron in 2010 and were diagnosed with an eye problem in 2011, you might be eligible.
Free Case Review
When you contact a lawyer about a prospective Elmiron vision injury case, they may inquire about your personal experiences with the medicine. Make sure you include as much information as possible while answering questions.
Case Review Form
Campaign guidance, records, and sources
Review the supporting information below before or after completing the private campaign form.
A practical checklist to help organize useful details before review.
Reviewed for intake accuracy by AMMS Compliance Team
Records and details that may help
- Prescription records showing Elmiron (pentosan polysulfate sodium) use, dosage, and duration
- Eye exam records, retinal imaging, and ophthalmologist or retinal specialist diagnosis information
- Timeline of vision symptoms relative to Elmiron use start and stop dates
- Prior attorney or claim inquiry history
Sources used for intake education
These official references are provided for background education only. They do not replace medical or legal advice.
- FDA Elmiron label update — pigmentary maculopathy warningFDA drug-approval database entry for Elmiron including labeling history and safety updates.
1. Submit the intake form
Share your contact details and answer the existing campaign-specific questions.
2. Organize supporting details
Gather the records, dates, communications, and other details listed for this campaign.
3. Intake follow-up
AMMS or an authorized intake partner may contact you for missing or clarifying details.
4. Legal review if appropriate
Qualified legal professionals decide whether a claim can move forward. AMMS does not provide legal advice or guarantee results.
Frequently asked questions
What vision problems are associated with Elmiron?
Pigmentary maculopathy, a form of retinal damage, has been associated with long-term Elmiron use. Symptoms may include blurred vision, difficulty reading, and changes in central vision.
How long does someone typically need to have used Elmiron for a review to be relevant?
Intake reviewers typically look for multi-year use, as the research linking Elmiron to maculopathy generally involves longer-term exposure. Provide the full duration of use when submitting.


